Clinical Trial Update: DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03] [Phase 3]

View source ↗

Summary

Phase 3 DESTINY-Breast03 compared trastuzumab deruxtecan (DS-8201a) with ado-trastuzumab emtansine (T-DM1) in HER2-positive unresectable/metastatic breast cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Enhertu (trastuzumab deruxtecan)
• Kadcyla (ado-trastuzumab emtansine)

Snippet

Sponsor: Daiichi Sankyo | Conditions: Breast Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2022-04-29